Indian pharma exports show resilience, near $29B with steady growth
04 Apr 2026

India's pharmaceutical exports have shown remarkable resilience this financial year, nearing the $29 billion mark by February. This growth comes even as global markets continue to be volatile.

K Raja Bhanu, Director General of the Pharmaceuticals Export Promotion Council of India (PHARMEXCIL), said that despite global challenges, pharmaceutical exports have maintained their growth momentum.

He noted a 5.6% increase in exports during April-February FY26 compared to the same period last fiscal year.

Industry's growth trajectory
Industry growth

The Indian pharmaceutical industry, currently valued at some $60 billion, is expected to more than double in size to $130 billion by 2030.

This projection highlights the sector's strong long-term growth prospects.

Despite pricing pressures and trade uncertainties in global markets, export performance has remained robust.

Shipments rose to $30.47 billion in FY 2024-25, marking a 9.4% year-on-year (YoY) increase over the previous fiscal year.

Key drivers of export growth
Fact

The growth of India's pharmaceutical exports has been largely driven by high-value segments like formulations, biologicals, and vaccines. The increasing traction in Ayush products has also contributed to this growth. These developments have helped India maintain its position as key global supplier of affordable medicines.